Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis
Cystic fibrosis (CF) is a autosomal recessive, multisystemic disease caused by different mutations in the CFTR gene encoding CF transmembrane conductance regulator. Although symptom management is important to avoid complications, the approval of CFTR modulator drugs in the clinic has demonstrated si...
Main Authors: | Jessica Conti, Claudio Sorio, Paola Melotti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Children |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9067/10/1/4 |
Similar Items
-
Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination
by: Karina Kleinfelder, et al.
Published: (2023-06-01) -
Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers
by: Fabiana Ciciriello, et al.
Published: (2022-04-01) -
Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis
by: Duncan E. Keegan, et al.
Published: (2021-04-01) -
Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype
by: Marika Comegna, et al.
Published: (2021-07-01) -
Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis
by: Tarini N. A. Gunawardena, et al.
Published: (2023-04-01)